Designs, manufactures, and markets ammunition and related components for hunters, recreational shooters, law enforcement, and military agencies. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.9× for every dollar of annual revenue.
Analysts' average target sits 10% below today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 12% a year on average.
A loss of $5.5M against $2.7B in annual sales. And on top of that, sales fell from the year before.
The stock trades 10% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.